KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Operating Expenses (2016 - 2025)

Emergent BioSolutions' Operating Expenses history spans 15 years, with the latest figure at $176.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 13.52% year-over-year to $176.6 million; the TTM value through Dec 2025 reached $642.8 million, down 44.22%, while the annual FY2025 figure was $642.8 million, 44.22% down from the prior year.
  • Operating Expenses reached $176.6 million in Q4 2025 per EBS's latest filing, up from $154.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $630.8 million in Q2 2023 to a low of $139.3 million in Q2 2025.
  • Average Operating Expenses over 5 years is $314.5 million, with a median of $306.5 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 100.44% in 2023, then tumbled 69.6% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $437.9 million in 2021, then fell by 11.97% to $385.5 million in 2022, then fell by 16.89% to $320.4 million in 2023, then crashed by 36.27% to $204.2 million in 2024, then dropped by 13.52% to $176.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Operating Expenses are $176.6 million (Q4 2025), $154.6 million (Q3 2025), and $139.3 million (Q2 2025).